These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1312304)

  • 21. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmission of serum parvovirus-like virus by clotting-factor concentrates.
    Mortimer PP; Luban NL; Kelleher JF; Cohen BJ
    Lancet; 1983 Aug; 2(8348):482-4. PubMed ID: 6136645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of hepatitis A virus transmission by high-purity solvent detergent treated coagulation factor concentrates in Scottish haemophiliacs.
    Watson HG; Ludlam CA; McOmish F; Dennis R; Hart H; Simmonds P
    Br J Haematol; 1995 Jan; 89(1):214-6. PubMed ID: 7833268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus.
    Morfini M; Longo G; Rossi Ferrini P; Azzi A; Zakrewska C; Ciappi S; Kolumban P
    Am J Hematol; 1992 Feb; 39(2):149-50. PubMed ID: 1550108
    [No Abstract]   [Full Text] [Related]  

  • 25. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
    Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
    Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
    Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
    Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
    Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
    Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
    Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P
    J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
    Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
    Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
    Goldsmith JM; Deutsche J; Tang M; Green D
    Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human parvovirus B19 infection in persons with haemophilia.
    Prowse C; Dow B; Pelly SJ; McIntosh E; Reading S; Lowe GD; Gibson B; Cachia P; Thomas A; Dennis R; Ludlam CA
    Thromb Haemost; 1998 Aug; 80(2):351. PubMed ID: 9716173
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purity of factor VIII concentrates and immune function in hemophiliacs.
    Farrugia A
    Blood; 1992 May; 79(10):2800-1. PubMed ID: 1586729
    [No Abstract]   [Full Text] [Related]  

  • 37. High cost, low volume care in haemophilia.
    Selway J
    BMJ; 1998 May; 316(7141):1391. PubMed ID: 9564014
    [No Abstract]   [Full Text] [Related]  

  • 38. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives in hemophilia treatment.
    Kessler CM
    Hematology Am Soc Hematol Educ Program; 2005; ():429-35. PubMed ID: 16304415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
    Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
    Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.